Q4 EPS Estimate for Knight Therapeutics Decreased by Analyst

Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Stifel Canada decreased their Q4 2024 earnings per share (EPS) estimates for shares of Knight Therapeutics in a report released on Thursday, November 7th. Stifel Canada analyst J. Keywood now expects that the company will earn $0.06 per share for the quarter, down from their prior estimate of $0.07. Stifel Canada has a "Strong-Buy" rating on the stock. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share.

Separately, Stifel Nicolaus upgraded Knight Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the company from C$5.75 to C$6.75 in a report on Tuesday, August 13th.

Knight Therapeutics Stock Down 1.7 %

Shares of TSE GUD traded down C$0.09 during mid-day trading on Monday, hitting C$5.17. The company had a trading volume of 148,802 shares, compared to its average volume of 67,794. The company has a market capitalization of C$523.26 million, a PE ratio of -26.30, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The firm has a 50-day simple moving average of C$5.74 and a two-hundred day simple moving average of C$5.75. The company has a current ratio of 3.41, a quick ratio of 1.79 and a debt-to-equity ratio of 7.62. Knight Therapeutics has a one year low of C$4.98 and a one year high of C$6.23.

Knight Therapeutics (TSE:GUD - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.05). The business had revenue of C$95.57 million for the quarter, compared to the consensus estimate of C$89.83 million. Knight Therapeutics had a negative return on equity of 2.70% and a negative net margin of 6.28%.

Insider Activity

In related news, Director Samira Sakhia acquired 20,000 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was bought at an average price of C$5.15 per share, for a total transaction of C$103,000.00. In related news, Senior Officer Amal Khouri sold 5,000 shares of the firm's stock in a transaction dated Monday, August 19th. The shares were sold at an average price of C$5.78, for a total value of C$28,919.00. Also, Director Samira Sakhia bought 20,000 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average price of C$5.15 per share, with a total value of C$103,000.00. Insiders sold 310,500 shares of company stock worth $1,899,544 in the last quarter. Corporate insiders own 45.62% of the company's stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.